August 08, 2024 11:19 GMT
Eli Lilly (LLY A1/A+/NR): 2Q24 Results
HEALTHCARE
Impressive results, small credit positive.
- Eli Lilly reports revenue 13% ahead of consensus, with sales of GLP-1 well ahead, helped by higher US prices.
- That drove an operating income beat of 28% / 48% adjusted.
- FY24 revenue guidance upped by 7%, operating margin by 4%. With consensus aligned with the old figures, massive upgrades ahead on this.
- Webcast 14.00 BST https://investor.lilly.com/events/event-details/q3....
Keep reading...Show less
61 words